Tanabe Pharma Corporation: Influenza, Human trials

The registry lists 11 Influenza, Human studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 7Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and OlderCompletedNCT04622592Phase 1/2Results posted
• Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy AdultsCompletedNCT03321968Phase 3Results posted
• Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsCompletedNCT03301051Phase 3Results posted
• Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly AdultsCompletedNCT02831751Phase 2
• Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy AdultsCompletedNCT02768805Phase 2
• Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly PopulationCompletedNCT02236052Phase 2
• Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in AdultsCompletedNCT02233816Phase 2
• Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.CompletedNCT02022163Phase 1
• Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsCompletedNCT01991587Phase 1/2
• Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.CompletedNCT01991561Phase 2
• Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in AdultsCompletedNCT01302990Phase 1